Moderna (MRNA) Stock Up 146% Year to Date Amid Market Rotation

Moderna, Inc. (NASDAQ: MRNA) is currently the 12th best-performing stock in the S&P 500, with a year-to-date gain of 146%. Despite this substantial increase, the company is still not profitable and does not expect to reach cash break-even until 2028, with earnings per share expected to turn positive only by 2029. This performance follows a period of stagnation post-COVID. Analysts highlight that while Moderna has promising prospects in cancer trials, investors are advised to wait for a pullback before buying, given the stock's significant rise.